SciELO - Scientific Electronic Library Online

vol.54 suppl.1Family healthcare expenditure on children affiliated to the Medical Insurance for a New GenerationPhysical growth and nutritional status of Mexican infants from newborn to two years of age author indexsubject indexarticles search
Home Page  

Services on Demand




Related links

  • Have no similar articlesSimilars in SciELO


Salud Pública de México

Print version ISSN 0036-3634


SALINAS-ESCUDERO, Guillermo et al. Economic evaluation of the use of exogenous pulmonary surfactants in preterm newborns in a Mexican population. Salud pública Méx [online]. 2012, vol.54, suppl.1, pp.s73-s81. ISSN 0036-3634.

OBJECTIVE: To estimate the cost-effectiveness ratio of surfactant rescue treatment of premature infants with respiratory distress syndrome (RDS) who are covered by the Medical Insurance for a New Generation. MATERIALS AND METHODS: A cost-effectiveness evaluation was conducted from the third-payer perspective. Comparisons were made between the use of bovine surfactant (BS) therapy and without BS therapy. A decision tree model with a lifetime horizon was used where the measurements of effectiveness were life years gained (LYG) and quality-adjusted life years (QALYs). A 5% discount rate was considered for costs and health outcomes. All costs are expressed in Mexican pesos 2009. RESULTS: Incremental cost-effectiveness ratios (ICER) were MXN$136670 per LYG and MXN$125250 per QALY. CONCLUSION: Surfactant therapy was confirmed as a cost-effective strategy in accordance with World Health Organization criteria of three per capita gross domestic product (GDP) per QALY in premature infants with RDS in Mexico.

Keywords : cost effectiveness; surfactant; respiratory distress syndrome; direct medical costs; life years gained; quality adjusted life years; Mexico.

        · abstract in Spanish     · text in English     · English ( pdf )